03 379 0555

Anna Fenton instrumental in developing new international menopause guidelines

Endocrinologist Dr Anna Fenton

Endocrinologist Dr Anna Fenton

The International Menopause Society (IMS) recently published its updated recommendations on women’s midlife health and menopause. The evidence-based guidelines were written by global experts in their fields, with our Endocrinologist Dr Anna Fenton sitting on the publication steering committee. In this article, Anna explains the key changes in the document, which has been created to guide medical professionals.

Updating the IMS guidelines was a two-year process that involved the rigorous analysis of all aspects of women’s midlife health. It will now be available as a living document that we can update as our knowledge of women’s health continues to evolve. One of the main recommendations to come out of the new guidelines is the way menopause is diagnosed. In the past, it was determined by changes to the menstrual cycle, but this did not consider all the other changes that happen to a person’s wellbeing during menopause. The new IMS document now suggests that if someone over 40 starts to experience moderate to severe bothersome vasomotor symptoms (VMS), like hot flushes and night sweats, then they should be assessed and provided treatment as needed. This acknowledges the fact that many people will notice symptoms before they experience changes in their periods. In fact, we know that about 30-35% of women in their mid to late-30s, will start experiencing symptoms due to a drop in estrogen.

Management options
The evidence is clear that Menopause Hormone Therapy (MHT) is the most effective treatment we have for managing menopause symptoms. The guidelines acknowledge that no two women are the same and all products won’t suit everyone. Therefore, if symptoms are not being well managed on a low to medium dose of MHT, General Practitioners may undertake further investigations and adjust the dose or the way it is delivered.

You may have seen social media influencers promote the need to routinely measure serum estradiol levels to ensure the right dose of MHT. However, this is not supported by evidence and not generally recommended. We would only measure estrogen levels if symptoms are not being relieved, the person experiences persistent adverse effects, has Premature Ovarian Insufficiency (POI), or is going through early menopause. If you are applying vaginal estrogen products, remember that it needs to be done after intercourse, not before, as cases have been reported where male partners have developed enlarged breasts (gynecomastia).

If you are unable to use MHT, new non-hormonal options are now available to consider. This new group of medications, known as neurokinin receptor antagonists, work by targeting neurons in the brain that are responsible for triggering hot flushes and sweating.

There’s a whole world of alternative and complementary therapies out there and many have been subjected to quite rigorous clinical trials. One of these medication-free options is Cognitive Behavioural Therapy (CBT), which the new guidelines rank highly. It is recommended as an effective non-hormonal therapy for managing symptoms in menopausal women and those who have had breast cancer. Clinical hypnosis is another option I recommend to patients fairly frequently. There is now reasonable data showing it can be effective at reducing the frequency and severity of hot flushes, sweating, sleep disturbance, and mood changes.

Quality of life
People often ask me whether dietary adjustments can help to stop the symptoms of menopause, but aside from avoiding specific triggers, such as alcohol or spicy food, there is no evidence to show they make a difference. Over the years, there has been a lot of interest in soy supplements. The evidence shows that soy products are unlikely to be harmful, but particularly high doses of soy or isoflavone supplementation are no longer recommended because of potential adverse effects on breast health and safety. For people with an increased breast cancer risk, or who have had breast cancer, we would not use anything with a high dose of soy supplementation.

Maintaining good quality sleep is so important during the transition through menopause. We know that poor sleep during this time is linked to poor health outcomes like changes to mood, cognition, and weight, as well as dementia risk, hypertension, cardiovascular disease, and diabetes. Sleep issues caused by night sweats and waking during the night can be improved by getting the estrogen dose in MHT right.

While obesity can worsen menopause symptoms, the guidelines signal that weight loss of even 5 to 10% can improve many of the issues linked to insulin resistance. The Mediterranean diet is considered the best eating plan to help mitigate some of these age-related changes, especially if calories are slightly reduced and exercise is increased.

Genitourinary syndrome of menopause
Genitourinary syndrome of menopause (GSM) is very common, involving a range of symptoms including dryness and discomfort during sex. It can greatly impact a woman's quality of life and relationships. To help manage these symptoms, your General Practitioner may prescribe you vaginal estrogen, along with lubricants and moisturisers.

Androgen therapy and testosterone use in women
The guidelines dedicate a chapter to androgen therapy written by Endocrinologist Prof Sue Davis, who has become well known as a global expert on this. One of Sue's major points is that the data does not support the use of testosterone for women for any symptom, condition, or disease prevention, other than post-menopausal low libido. Social media influencers continue to promote a message that testosterone is a cure-all for all menopausal conditions, but at this stage it’s not backed by science. You may be surprised to know that over a woman's lifespan, testosterone declines from about 20 years of age to the mid to late 50s. It then starts to rise again, so by the time a woman reaches her 80s, levels return to that of what they were in her much younger years. This means that testosterone may not be needed in the long-term but will need to be reviewed and monitored over time. Interestingly when it comes to libido, hormones only play about a 5% role, with the rest linked to life’s stresses, underlying medical conditions, medications, and relationships, so these factors need to be taken into account if you are discussing the use of testosterone with your General Practitioner.

Midlife health

Weight
One of the most difficult symptoms to manage during menopause is weight gain and the changes to body composition. We are still learning the drivers behind this, but a likely cause is a decrease in energy output. Estrogen-based hormone therapy won’t stop weight gain but it can help to reduce body fat redistribution and lower insulin resistance with the right dose and formulation.

Heart and stroke risk
Estrogen significantly reduces coronary heart disease in women who are under 60, or who are recently post-menopausal without pre-existing heart issues. Various research has shown consistent benefits when it is started before 60 or within 10 years of menopause. This can halve the risk of heart disease. Interestingly, for most women, there doesn't appear to be an increase in stroke risk, regardless of the kind of estrogen used in women starting it at menopause. Generally, women who start taking MHT under 10 years after their last menstrual period, or before they turn 60, are at similar risk of stroke compared to women who don't take it. Some women such as those who are overweight, have hypertension or suffer from migraines are safest on estrogen delivered through the skin rather than orally. Once women women reach their 60s, patch or gel estrogen is associated with a lower risk of stroke, compared with higher oral doses.

Osteoporosis
MHT is considered a first-line therapy for the prevention of bone loss during menopause and significantly reduces the risk of osteoporosis-related fractures. The benefits are most likely to outweigh any risks when started within 10 years of menopause or before 60.

Sarcopenia
Age-related muscle mass loss worsens at menopause because of hormonal changes and reduced estrogen. To maintain muscle, it is important to continue aerobic and resistance physical exercise, which can be as simple as starting with low weights and building them up over time. There is reasonable evidence that suggests people doing regular exercise may benefit from adding protein (whey and leucine), creatine, or L-citrulline to their diet. They only work in tandem though, so exercise cannot be avoided.

Skin, cartilage, connective tissues
Estrogen plays a role in all the connective tissues in our body. This is why we start to see issues like dry skin and hair, hair loss, tendon injuries, and a loss of joint fluid during menopause. We’re also learning more about the role ovarian hormones play in autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, which can worsen during early menopause. MHT does, however, appear to be quite safe to use without aggravating the underlying conditions.

Central nervous system
Estrogen Therapy (ET) can prevent dementia in women with Premature Ovarian Insufficiency (POI) and early menopause. It is also associated with a lower risk of dementia in premenopausal women who undergo surgery to remove the ovaries. We would offer estrogen replacement on these occasions until the normal age of menopause, because women undergoing a premature menopause because of surgery are at double to triple the risk of dementia. There is no data to recommend starting MHT to prevent dementia in naturally menopausal women.

Cancers
It’s important to note that the risk of breast cancer linked to MHT is small, and similar to or less than common lifestyle factors, such as physical inactivity, obesity, and alcohol consumption. The slight increased risk of breast cancer is mostly due to the choice of progestogen in MHT and how long it is used for.

Premature ovarian insufficiency
Premature ovarian insufficiency (POI) is an important condition that needs to be diagnosed and managed appropriately. It means menopause arrives before the age of 40 years and this affects 4% of the female population. Women with POI should be offered MHT. Without it, they are exposed to long-term health risks, such as cardiovascular disease, stroke, mental health disorders, dementia, Parkinson's disease, and fractures. It also needs to be continued until the normal age of menopause and reviewed.